Pharvaris BV

Stock Chart, Company Information, and Scan Results

$30.13(as of Jun 3, 3:57 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Pharvaris BV Company Information, Fundamentals, and Technical Indicators

Stock Price$30.13
Ticker SymbolPHVS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees134
CountyUSA
Market Cap$2,025.1M

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris BV In Our Stock Scanner

As of Jun 04, 2026
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.